Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 3/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845045 | 1.00 | CTSS (0.55) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL30461851 | 1.00 | CTSS (0.55) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL5845049 | 1.00 | CTSS (0.55) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL5153113 | 0.90 | ACE (0.52) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL27207089 | 0.90 | ACE (0.52) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL27203773 | 0.90 | ACE (0.52) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL268952 | 0.90 | PTPN1 (0.55) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL1509242 | 0.90 | PTPN1 (0.55) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL268951 | 0.90 | PTPN1 (0.55) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL864799 | 0.89 | PTPN1 (0.54) | CTSSCTSKPTPN1ACESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059175-A1 | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-02-20 | — | — | US | disclosed |
| WO-2025038815-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2023107597-A2 | BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2007096186-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| EP-0763026-B1 | GASTRIN AND CCK ANTAGONISTS | BLACK JAMES FOUNDATION (GB) | 2003-03-26 | — | — | EP | disclosed |
| EP-0720601-B1 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2000-10-25 | — | — | EP | disclosed |
| US-5919829-A | Gastrin and cck receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5912260-A | GASTRIC ACID SECRETION | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-06-15 | — | — | US | disclosed |
| US-5795907-A | Gastin and CCK receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-08-18 | — | — | US | disclosed |
| EP-0720601-A1 | GASTRIN AND CCK RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995004720-A2 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059175-A1 | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | PIK3CA, PIK3CD, PIK3R5 | CTSS 2804/4885CTSK 2347/4885PTPN1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.